Cytek Biosciences DB:8EQ Stok Raporu Şirket Finansalları + 6 Analistler
Cytek Biosciences, Inc.
DB:8EQ Stok Raporu
8EQ Stoklara Genel Bakış Bir hücre analizi çözümleri şirketi olan Cytek Biosciences, Inc. biyomedikal araştırmalarda ve klinik uygulamalarda bilimsel ilerlemeleri kolaylaştıran hücre analizi araçları sağlamaktadır. Daha fazla detay
Ödüller Risk Analizi Tüm Risk Kontrollerini Gör Cytek Biosciences, Inc. Rakipler Fiyat Geçmişi ve Performans
için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Cytek Biosciences Tarihsel hisse senedi fiyatları Güncel Hisse Fiyatı US$6.55 52 Haftanın En Yüksek Seviyesi US$6.90 52 Haftanın En Düşük Seviyesi US$4.20 Beta 1.32 11 Aylık Değişim 45.56% 3 Aylık Değişim 38.19% 1 Yıllık Değişim 92.65% 33 Yıllık Değişim -67.25% 5 Yıllık Değişim n/a Halka arzdan bu yana değişim -68.05%
Son Haberler & Güncellemeler
Cytek Biosciences, Inc. Introduces an Enhanced Small Particle Detection Option for Its Cytek Aurora Cs System Nov 08
New major risk - Share price stability Nov 08
Third quarter 2024 earnings released: EPS: US$0.007 (vs US$0.047 loss in 3Q 2023) Nov 07
Cytek Biosciences, Inc. Reaffirms Earnings Guidance for the Year 2024 Nov 06
Cytek Biosciences, Inc. to Report Q3, 2024 Results on Nov 05, 2024 Oct 30
Cytek Biosciences, Inc. Announces Resignation of Paul Christopher Williams as Chief Operating Officer, Effective September 27, 2024 Sep 12 Daha fazla güncelleme görün
Cytek Biosciences, Inc. Introduces an Enhanced Small Particle Detection Option for Its Cytek Aurora Cs System Nov 08
New major risk - Share price stability Nov 08
Third quarter 2024 earnings released: EPS: US$0.007 (vs US$0.047 loss in 3Q 2023) Nov 07
Cytek Biosciences, Inc. Reaffirms Earnings Guidance for the Year 2024 Nov 06
Cytek Biosciences, Inc. to Report Q3, 2024 Results on Nov 05, 2024 Oct 30
Cytek Biosciences, Inc. Announces Resignation of Paul Christopher Williams as Chief Operating Officer, Effective September 27, 2024 Sep 12
Second quarter 2024 earnings released: US$0.079 loss per share (vs US$0.032 loss in 2Q 2023) Aug 07 Cytek Biosciences, Inc. Narrows Earnings Guidance for the Year 2024 Aug 07
Cytek Biosciences, Inc. Automates Panel Design with New Intelligent Algorithm Cytek Biosciences, Inc. (NasdaqGS:CTKB) announces an Equity Buyback for $50 million worth of its shares. Jun 08
Cytek Biosciences, Inc. Reaffirms Earnings Guidance for the Year Ending December 31, 2024 May 10
Cytek Biosciences, Inc. to Report Q1, 2024 Results on May 08, 2024 May 01
Cytek Biosciences, Inc., Annual General Meeting, Jun 05, 2024 Apr 28 Cytek Biosciences, Inc. Announces Appointment of Patrik Jeanmonod as Head of Corporate Development Analytics Cytek Biosciences, Inc. announced delayed annual 10-K filing Mar 03
Cytek Biosciences, Inc. Provides Earnings Guidance for the Year Ended December 31, 2024 Mar 01
Cytek Biosciences, Inc. to Report Q4, 2023 Results on Feb 28, 2024 Feb 08
Cytek Biosciences, Inc. Provides Revenue Guidance for the Year 2023 Jan 08
Cytek Biosciences Introduces the Cytek Orion™ Reagent Cocktail Preparation System, the First-of-its-Kind Automated Cocktail Preparation Instrument for Flow Cytometry Dec 21
Cytek Biosciences, Inc. announced delayed 10-Q filing Nov 15
Cytek Biosciences, Inc. announced delayed 10-Q filing Nov 14
Third quarter 2023 earnings released: US$0.047 loss per share (vs US$0.012 profit in 3Q 2022) Nov 10
Cytek Biosciences, Inc. Provides Revenue Guidance for the Year 2023 Nov 08
Cytek Biosciences, Inc. to Report Q3, 2023 Results on Nov 07, 2023 Oct 20
New minor risk - Share price stability Oct 06
Cytek Biosciences Appoints Dr. Philippe Busque Senior Vice President of Global Sales & Services Aug 29
Second quarter 2023 earnings released: US$0.032 loss per share (vs US$0.004 loss in 2Q 2022) Aug 09
Cytek Biosciences, Inc. Provides Revenue Guidance for the Full Year 2023 Aug 09
Cytek Biosciences, Inc. to Report Q2, 2023 Results on Aug 08, 2023 Jul 23
Cytek Biosciences, Inc. (NasdaqGS:CTKB) announces an Equity Buyback for $50 million worth of its shares. May 20
First quarter 2023 earnings released: US$0.05 loss per share (vs US$0.015 loss in 1Q 2022) May 11
Cytek Biosciences, Inc. Revises Earnings Guidance for the Year 2023 May 10
Full year 2022 earnings released: EPS: US$0.018 (vs US$0.001 in FY 2021) Mar 02
Cytek Biosciences, Inc. (NasdaqGS:CTKB) entered into an agreement to acquire Flow Cytometry & Imaging (FCI) business unit of Luminex Corporation for $46.5 million. Feb 14
Cytek Biosciences, Inc. to Report Q4, 2022 Results on Feb 28, 2023 Feb 08
Cytek Biosciences, Inc. Introduces Cytek Cloud Nov 16
Third quarter 2022 earnings released: EPS: US$0.012 (vs US$0.003 in 3Q 2021) Nov 11
Cytek Biosciences, Inc. Provides Revenue Guidance for the Year 2022 Nov 10
Cytek Biosciences, Inc. Names Chris Williams Chief Operating Officer Nov 01
Cytek Biosciences, Inc. to Report Q3, 2022 Results on Nov 09, 2022 Oct 27
Second quarter 2022 earnings released Aug 12
Cytek Biosciences, Inc. Provides Earnings Guidance for the Full Year 2022 Aug 11
Cytek Biosciences, Inc. to Report Q2, 2022 Results on Aug 10, 2022 Jul 21
Cytek Biosciences, Inc.(NasdaqGS:CTKB) dropped from Russell 2500 Value Index Jun 26
Cytek Biosciences, Inc. Reaffirms Earning Guidance for 2022 Jun 24
Cytek Biosciences, Inc. Elects Deborah Neff, Don Hardison as Class I Director Jun 07
First quarter 2022 earnings released May 13
Cytek Biosciences, Inc. Provides Revenue Guidance for the Full Year 2022 May 12
Cytek Biosciences, Inc., Annual General Meeting, Jun 01, 2022 Apr 15
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Feb 28
Cytek Biosciences, Inc. Provides Revenue Guidance for the Fiscal Year 2022 Feb 24
Cytek Biosciences, Inc. to Report Q4, 2021 Results on Feb 23, 2022 Feb 12 Hissedar Getirileri 8EQ DE Life Sciences DE Pazar 7D 24.8% 1.7% -0.2% 1Y 92.6% 9.0% 7.8%
Hissedar getirilerinin tamamını görün
Getiri vs. Endüstri: 8EQ geçen yıl % 9 oranında getiri sağlayan German Life Sciences sektörünü aştı.
Getiri vs Piyasa: 8EQ geçen yıl % 7.8 oranında getiri sağlayan German Piyasasını aştı.
Fiyat Oynaklığı Is 8EQ's price volatile compared to industry and market? 8EQ volatility 8EQ Average Weekly Movement 11.5% Life Sciences Industry Average Movement 6.1% Market Average Movement 4.8% 10% most volatile stocks in DE Market 10.7% 10% least volatile stocks in DE Market 2.4%
İstikrarlı Hisse Senedi Fiyatı: 8EQ hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.
Zaman İçindeki Volatilite: 8EQ 'nin haftalık oynaklığı ( 11% ) geçen yıl boyunca sabit kaldı, ancak hala German hisselerinin %75'inden yüksek.
Şirket Hakkında Kuruldu Çalışanlar CEO Web sitesi 1992 645 Wenbin Jiang cytekbio.com
Bir hücre analizi çözümleri şirketi olan Cytek Biosciences, Inc. biyomedikal araştırmalarda ve klinik uygulamalarda bilimsel ilerlemeleri kolaylaştıran hücre analizi araçları sağlamaktadır. Tek hücrelerdeki floresan etiketleri ayırt etmek için birden fazla lazerden gelen floresan imzalarını kullanarak hücre analizi sağlayan spektrum akış sitometreleri olan aurora ve kuzey ışıkları sistemleri; ve hücre analizindeki potansiyel uygulamaları daha da genişletmek için tam spektrum profilleme teknolojisinden yararlanan aurora hücre sıralayıcı sistemi; aurora CS sistemleri; amnis imagestream görüntüleme akış sitometreleri; guava muse hücre analizörleri; guava easycyte akış sitometreleri; ve orion reaktif kokteyli hazırlama sistemleri sunmaktadır. Şirket ayrıca, cihazlarında analiz için ilgili hücreleri tanımlamak için kullanılan florokrom konjuge antikorlar olan cFluor reaktiflerinin yanı sıra TBNK hücreleri, monositler, dendritik hücreler ve bazofiller için ana insan bağışıklık alt popülasyonlarını tanımlamak için anahtar teslimi çözümler sunan 25 renkli immünoprofilleme testi de dahil olmak üzere reaktifler ve kitler sunmaktadır.
Daha fazla göster Cytek Biosciences, Inc. Temel Bilgiler Özeti Cytek Biosciences'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır? 8EQ temel i̇stati̇sti̇kler Piyasa değeri €858.76m Kazançlar(TTM ) -€9.62m Gelir(TTM ) €190.55m
Kazanç ve Gelir En son kazanç raporundan temel karlılık istatistikleri (TTM) 8EQ gelir tablosu (TTM ) Gelir US$201.21m Gelir Maliyeti US$90.71m Brüt Kâr US$110.50m Diğer Giderler US$120.66m Kazançlar -US$10.16m
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
